CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Incyte Corporation
Amgen
Dren Bio
Miltenyi Biomedicine GmbH
AstraZeneca
BeOne Medicines
Quetzal Therapeutics
AVM Biotechnology Inc
BeOne Medicines
AstraZeneca
Immunome, Inc.
BeOne Medicines
BeOne Medicines
Orca Biosystems, Inc.
BeOne Medicines
BeOne Medicines
Janssen Research & Development, LLC
Nurix Therapeutics, Inc.
Kura Oncology, Inc.
Pfizer
Incyte Corporation
Nurix Therapeutics, Inc.
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Genmab
Grifols Therapeutics LLC
Chordia Therapeutics, Inc.
Janssen Research & Development, LLC
AbbVie
Merck Sharp & Dohme LLC
GluBio Therapeutics Inc.
Janssen Cilag S.A.S.
AstraZeneca
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Beijing InnoCare Pharma Tech Co., Ltd.
Moleculin Biotech, Inc.
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Beijing Biotech
AbbVie
Kura Oncology, Inc.
TScan Therapeutics, Inc.
Bristol-Myers Squibb
Genmab
Seagen Inc.
AstraZeneca